Extended Duration of Adjuvant Temozolomide in Glioblastoma Multiforme – A Review of Trials
Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy then adjuvant TMZ is the current standard treatment for glioblastoma multiforme (GBM). There is a lot of controversy regarding the duration of adjuvant TMZ. The standard guidelines recommend 6 months of adjuvant treatment, however in clinical practice in a lot of centers around the world, TMZ therapy is continued beyond 6 months duration. In this review article we will discuss both favorable and unfavorable trials regarding extended TMZ therapy and try to analyze in whom extended TMZ therapy is beneficial and whether or not it should be offered.
1.Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, O'Neill B, et al. A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? Br J Radiol 2012;85:e729–33.
2. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Survival time trends of glioblastoma using the SEER 17 population-based registries. J Neuro Oncol 2012;107:207–12. [CrossRef]
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987– 96. [CrossRef]
4. Price RL, Chiocca EA. Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. Neurosurgery 2014;61 Suppl 1:74–83. [CrossRef]
5. Vand Rajabpour M, Yahyazadeh H, Beheshti M. Prognostic Factors and Survival of Glioblastoma Multiform (GBM) in Iranian Patients. Int J Cancer Manag 2017;10:e6260. [CrossRef]
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.
7. NCNN physician guidelines. Available at: https://www.nccn. org/professionals/physician_gls/default.aspx#cns. Accessed Feb 19, 2021.
8. Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 2007;68:688– 90. [CrossRef]
9. Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, et al. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a singleinstitution experience with as many as 101 temozolomide cycles. Neurosurg Focus 2014;37:E4. [CrossRef]
10. Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L, Auberdiac P, et al. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol 2012;106:127–33. [CrossRef]
11. Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B, et al. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res 2013;33:3467–74.
12. Bhandari M, Gandhi AK, Devnani B, Kumar P, Sharma DN, Julka PK. Comparative study of adjuvant temozolomide six cycles versus extended 12 cycles in newly diagnosed glioblastoma multiforme. J Clin Diagn Res 2017;11:XC04–XC08. [CrossRef]
13. Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, etal. Prolonged temozolomide maintenance therapy in newly diagnosed glioblastoma. Oncologist 2017;22:570–5.
14. Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, et al. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol 2017;19:1119–26.
15. Refae AA, Ezzat A, Salem DA, Mahrous M. Protracted adjuvant temozolomide in glioblastoma multiforme. J Cancer Ther 2015;6:748 [CrossRef]
16. Alimohammadi E, Bagheri SR, Taheri S, Dayani M, Abdi A. The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review. Oncol Rev 2020;14:461.
17. Seiz M, Krafft U, Freyschlag CF, Weiss C, Schmieder K, Lohr F, et al. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol 2010;136:1691–5.
18. Roldán Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncol 2012;108:173–7.
19. Rivoirard R, Falk AT, Chargari C, Guy JB, Mery B, Nuti C, et al. Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study). Clin Oncol (R Coll Radiol) 2015;27:486–7. [CrossRef]
20. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019;393:678–88. [CrossRef]
21. Liu Y, Hao S, Yu L, Gao Z. Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review. World J Surg Oncol 2015;13:142.
22. Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, et al. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology 2017;88:1422–30. [CrossRef]
23. Balana C, Vaz MA, Manuel Sepúlveda J, Mesia C, Del Barco S, Pineda E, et al. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Neuro Oncol 2020;22:1851–61. [CrossRef]
24. Tejpal Gupta, Abhishek Chatterjee, Vijay Patil. Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less? Comment on “A phase II randomized, multicenter, openlabel trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)”. Neuro Oncol 2020;22:1887–8. [CrossRef]